Review Article
A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
Table 4
Selected new or ongoing clinical trials of PD-1/PD-L1 inhibitors for the treatment of urothelial carcinoma.
| NCT identifier | Interventions | Recruitment | Phases | Locations |
| NCT03113266 | Anti-PD-1 monoclonal antibody | Recruiting | Phase 2 | China | NCT03287050 | Pembrolizumab/radiation | Not yet recruiting | Early phase 1 | United States | NCT03240016 | Pembrolizumab/abraxane | Not yet recruiting | Phase 2 | United States | NCT02807636 | Atezolizumab/carboplatin/gemcitabine/cisplatin/placebo | Recruiting | Phase 3 | Globe | NCT02853305 | Pembrolizumab/cisplatin/carboplatin/gemcitabine | Recruiting | Phase 3 | Globe | NCT03219775 | Nivolumab/ipilimumab | Recruiting | Phase 2 | Germany | NCT02500121 | Pembrolizumab/placebo | Recruiting | Phase 2 | United States | NCT02450331 | Atezolizumab | Recruiting | Phase 3 | Globe | NCT03115801 | Atezolizumab/radiation | Recruiting | Phase 2 | United States | NCT03244384 | Pembrolizumab/clinical observation/biomarker analysis | Recruiting | Phase 3 | United States | NCT02451423 | Atezolizumab dose level 1/dose level 2/dose level 3 | Recruiting | Phase 2 | United States | NCT02897765 | NEO-PV-01/nivolumab/adjuvant | Recruiting | Phase 1 | United States | NCT02845323 | Nivolumab + urelumab/nivolumab monotherapy | Recruiting | Phase 2 | United States | NCT02736266 | Pembrolizumab | Recruiting | Phase 2 | Italy | NCT03237780 | Atezolizumab/eribulin mesylate/biomarker analysis | Not yet recruiting | Phase 2 | United States |
|
|